NEW YORK (GenomeWeb) – Molecular Profiles and Xceleron today announced a collaboration to help drug developers improve efficiency during the clinical development stage.
Xceleron's knowledge in using accelerator mass spectrometry technology in pharma applications will be added to Molecular Profiles' new Roadmap to Clinical Trials platform, launched earlier this month. The screening platform incorporates Molecular Profiles' existing formulation and analytical development modules to streamline the development of drugs.
The deal aims to improve the quality and accuracy of clinical data and to support early proof-of-concept research in order to "assist drug innovators with more assured translation," the partners said in a statement.
"Looking at Molecular Profiles' Roadmap to Clinical Trials platform, we believe there is an opportunity to add our complementary analytical technology to the process," Xceleron CEO Michael Butler said. "This gives our clients the option to investigate the impact of solid state and formulations on human disposition at a very early stage."
Based in Nottingham, UK, Molecular Profiles is a subsidiary of Columbia Laboratories. It is a contract development and manufacturing organization specializing in early phase pharmaceutical development.
Xceleron provides analytical services based on accelerator mass spec technology, primarily for pharma R&D. It is headquartered in Germantown, Md.
Financial and other terms of the deal were not disclosed.